ATE481108T1 - Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen - Google Patents

Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen

Info

Publication number
ATE481108T1
ATE481108T1 AT99930126T AT99930126T ATE481108T1 AT E481108 T1 ATE481108 T1 AT E481108T1 AT 99930126 T AT99930126 T AT 99930126T AT 99930126 T AT99930126 T AT 99930126T AT E481108 T1 ATE481108 T1 AT E481108T1
Authority
AT
Austria
Prior art keywords
adjuvants
antigens
bioadhaesives
mucosal application
compositions
Prior art date
Application number
AT99930126T
Other languages
English (en)
Inventor
Manmohan Singh
Derek O'hagan
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE481108T1 publication Critical patent/ATE481108T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Adhesives Or Adhesive Processes (AREA)
AT99930126T 1999-02-26 1999-05-28 Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen ATE481108T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12217299P 1999-02-26 1999-02-26
PCT/US1999/011906 WO2000050078A1 (en) 1999-02-26 1999-05-28 Use of bioadhesives and adjuvants for the mucosal delivery of antigens

Publications (1)

Publication Number Publication Date
ATE481108T1 true ATE481108T1 (de) 2010-10-15

Family

ID=22401126

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99930126T ATE481108T1 (de) 1999-02-26 1999-05-28 Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen

Country Status (10)

Country Link
US (1) US20050281843A1 (de)
EP (2) EP1154793B1 (de)
JP (2) JP2002537355A (de)
AT (1) ATE481108T1 (de)
AU (1) AU4673099A (de)
CA (1) CA2366688A1 (de)
DE (1) DE69942774D1 (de)
ES (1) ES2350306T3 (de)
PT (1) PT1154793E (de)
WO (1) WO2000050078A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
WO2008037033A1 (en) * 2006-09-29 2008-04-03 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Flu vaccine admixture of mannan and flu antigen
AU2002305914A1 (en) * 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
DK1997478T3 (da) 2001-02-15 2013-12-09 Access Pharma Inc Flydende formuleringer til forebyggelse og behandling af slimhindesygdomme og -lidelser
ITMI20010571A1 (it) * 2001-03-19 2002-09-19 Grisotech S A Vaccini assorbibili per via trans-mucosale
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
GB0218921D0 (en) * 2002-08-14 2002-09-25 Glaxosmithkline Biolog Sa Novel vaccine
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
EP1945247A1 (de) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische immunisierungen mit alphavirus-replicon-teilchen
EP2019686B1 (de) 2006-03-31 2012-07-11 Novartis AG Kombinierte mukosale und parenterale immunisierung gegen hiv
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
EP2152304B1 (de) 2007-05-02 2018-08-22 The Regents of the University of Michigan Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
EP2293814A4 (de) * 2008-05-23 2013-02-13 Univ Michigan Nanoemulsionshilfsstoffe
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
AU2010232180B2 (en) * 2009-03-31 2016-09-22 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
EP3020412B1 (de) 2009-06-16 2017-10-11 The Regents of the University of Michigan Nanoemulsionsimpfstoffe
EP2515661A4 (de) * 2009-12-23 2013-11-13 Vaxgene Corp Immunschutz durch orale verabreichung von minikapseln mit rekombinantem lactococcus lactis
WO2011116262A2 (en) * 2010-03-19 2011-09-22 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9433644B2 (en) 2013-07-25 2016-09-06 Rutgilli Pharmaceuticals, Llc Formulations and methods for treating oral inflammation, injury, or pain
EP3063171B1 (de) 2013-11-01 2019-07-24 University Of Oslo Albuminvarianten und verwendungen davon
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
EP4112076A1 (de) 2014-10-10 2023-01-04 The Regents of The University of Michigan Nanoemulsionszusammensetzungen zur prävention, unterdrückung oder eliminierung von allergischen und entzündlichen erkrankungen
EP3268034A4 (de) 2015-03-05 2018-11-14 Northwestern University Nichtneuroinvasive viren und verwendungen davon
TW201709926A (zh) * 2015-04-23 2017-03-16 賽諾菲公司 用於舌下投藥之吡喃葡萄糖基脂ａ及過敏原調配物
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
CN109071631B (zh) 2016-03-14 2023-07-14 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
EP3454891A4 (de) 2016-05-10 2019-12-25 The Regents of The University of Michigan Emulsionsadjuvans zur intramuskulären, intradermalen und subkutanen verabreichung
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
EP3471761A2 (de) 2016-06-21 2019-04-24 University Of Oslo Hla-bindende impfstoffeinheiten und verwendungen davon
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
NL2018155B1 (en) 2017-01-11 2018-07-25 Intervet Int Bv Oral vaccine against ruminant respiratory disease
EP3678698A1 (de) 2017-09-07 2020-07-15 University Of Oslo Impfstoffmoleküle
EP3678699A1 (de) 2017-09-07 2020-07-15 University Of Oslo Impfstoffmoleküle
KR102092258B1 (ko) * 2018-05-23 2020-03-23 가톨릭대학교 산학협력단 광감각제가 접합된 고분자를 유효성분으로 포함하는 면역증강제, 바이러스 감염 또는 암 예방 또는 치료용 백신 조성물
EP4313132A1 (de) 2021-03-31 2024-02-07 Vib Vzw Impfstoffzusammensetzungen für trypanosomatide
GB202205231D0 (en) * 2022-04-09 2022-05-25 Nasaleze Patents Ltd Vaccine compositions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS523342B2 (de) 1972-01-26 1977-01-27
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
JPS5873993U (ja) 1981-11-12 1983-05-19 三菱電機株式会社 ２気筒回転式圧縮機
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US5324513A (en) 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5098704A (en) 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
JP2661044B2 (ja) 1986-06-17 1997-10-08 カイロン コーポレイション 肝炎δの診断薬およびワクチン
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
WO1990014436A1 (en) 1989-05-18 1990-11-29 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
CN1120310A (zh) * 1993-03-11 1996-04-10 塞科雷泰克公司 在粘膜表面转运免疫原的聚合粘膜粘合剂
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
ES2170853T3 (es) 1995-03-28 2002-08-16 Fidia Advanced Biopolymers Srl Nanosferas que comprenden un polisacarido biocompatible.
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
WO2011130539A2 (en) 2010-04-14 2011-10-20 Northwestern University Liquid cast biodegradable arterial stent
US12453398B1 (en) 2025-07-30 2025-10-28 Clarissa Alison Cuevas Self determined weight container

Also Published As

Publication number Publication date
PT1154793E (pt) 2010-12-21
DE69942774D1 (de) 2010-10-28
US20050281843A1 (en) 2005-12-22
AU4673099A (en) 2000-09-14
EP1154793B1 (de) 2010-09-15
EP1154793A1 (de) 2001-11-21
ES2350306T3 (es) 2011-01-20
CA2366688A1 (en) 2000-08-31
JP2002537355A (ja) 2002-11-05
WO2000050078A1 (en) 2000-08-31
EP2275133A1 (de) 2011-01-19
JP2011006495A (ja) 2011-01-13

Similar Documents

Publication Publication Date Title
DE69942774D1 (de) Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
DE69916581D1 (de) Eine universelle immunmodulatorische cytokin-expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
IL149459A0 (en) Recombinant gelatins
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
EG23427A (en) Cultivated agarwood.
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
DK1790660T3 (da) Heterolog ekspression af Neisseria-proteiner
ATE407987T1 (de) Neue mesogene, verfahren zu deren herstellung und verwendung
PL1638937T3 (pl) Krystaliczna postać XIV soli sodowej fluwastatyny, sposoby jej wytwarzania, kompozycje farmaceutyczne zawierające tę postać oraz sposoby ich stosowania
DE60305200D1 (de) Aminocyclohexylether-verbindungen und deren verwendung
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
MXPA05002418A (es) Derivados de 1,4-pirazina sustituidos.
DE60137607D1 (de) Substituierte cyclohexene
ATE285250T1 (de) Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien
ATE312842T1 (de) Reduziertes cortisolkonjugat
DE502005001632D1 (de) Verfahren zur herstellung von 1,3,5-triazincarbamaten und -harnstoffen
AU2002360330A1 (en) Identifying and reducing the allergenicity of food proteins
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
ATE335766T1 (de) Antikörper gegen caspase-8, ihre herstellung und verwendung
SE0100374D0 (sv) Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1154793

Country of ref document: EP